memantine has been researched along with Cortical Lewy Body Disease in 29 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effect on survival of treatment with memantine in patients with dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD)." | 9.19 | Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. ( Aarsland, D; Ballard, C; Larsson, V; Londos, E; Minthon, L; Stubendorff, K, 2014) |
| "To investigate quality of life (QOL) and the effect of memantine treatment in patients with Lewy body dementias." | 9.15 | Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson's disease dementia. ( Aarsland, D; Engedal, K; Larsson, V; Londos, E; Minthon, L; Wattmo, C, 2011) |
| "Previous studies have suggested that patients with Lewy-body-related dementias might benefit from treatment with the N-methyl D-aspartate receptor antagonist memantine, but further data are needed." | 9.14 | Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. ( Bladström, A; Bonuccelli, U; Ceballos-Baumann, A; Destée, A; Emre, M; Jones, R; Kutzelnigg, A; Tolosa, E; Tsolaki, M; Zdravkovic, S, 2010) |
| "To report on a patient with Lewy body dementia who developed worsening of hallucinations with memantine withdrawal and significant improvement with reinitiation of the drug." | 8.89 | Visual hallucinations treated with the reinitiation of memantine in a patient with Lewy body dementia. ( Blaszczyk, AT; Mathys, ML; McCarrell, J; Sleeper, RB, 2013) |
| "Three patients with probable dementia with Lewy bodies (DLB) experienced worsening delusions and visual hallucinations as a result of memantine therapy." | 7.73 | Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. ( Josephs, KA; Ridha, BH; Rossor, MN, 2005) |
| "To investigate the effect on survival of treatment with memantine in patients with dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD)." | 5.19 | Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. ( Aarsland, D; Ballard, C; Larsson, V; Londos, E; Minthon, L; Stubendorff, K, 2014) |
| "To investigate quality of life (QOL) and the effect of memantine treatment in patients with Lewy body dementias." | 5.15 | Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson's disease dementia. ( Aarsland, D; Engedal, K; Larsson, V; Londos, E; Minthon, L; Wattmo, C, 2011) |
| "Previous studies have suggested that patients with Lewy-body-related dementias might benefit from treatment with the N-methyl D-aspartate receptor antagonist memantine, but further data are needed." | 5.14 | Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. ( Bladström, A; Bonuccelli, U; Ceballos-Baumann, A; Destée, A; Emre, M; Jones, R; Kutzelnigg, A; Tolosa, E; Tsolaki, M; Zdravkovic, S, 2010) |
| "To report on a patient with Lewy body dementia who developed worsening of hallucinations with memantine withdrawal and significant improvement with reinitiation of the drug." | 4.89 | Visual hallucinations treated with the reinitiation of memantine in a patient with Lewy body dementia. ( Blaszczyk, AT; Mathys, ML; McCarrell, J; Sleeper, RB, 2013) |
| "Three patients with probable dementia with Lewy bodies (DLB) experienced worsening delusions and visual hallucinations as a result of memantine therapy." | 3.73 | Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. ( Josephs, KA; Ridha, BH; Rossor, MN, 2005) |
| " After memantine was started he developed severe fluctuations in awareness, visual hallucinations, agitation, and worsened parkinsonism." | 3.73 | Exacerbation of Lewy bodies dementia due to memantine. ( Blazquez-Menes, B; Calatayud, MT; Menendez-Gonzalez, M, 2005) |
| "A randomised double-blind, placebo-controlled, 24-week three centre trial of memantine (20 mg/day) was conducted in which tests of attention (simple and choice reaction time) and word recognition (immediate and delayed) from the CDR System were administered prior to dosing and again at 12 and 24 weeks." | 2.80 | Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. ( Aarsland, D; Ballard, C; Londos, E; Wesnes, KA, 2015) |
| "Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are common forms of dementia that substantially affect quality of life." | 2.74 | Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. ( Aarsland, D; Alves, G; Ballard, C; Bostrom, F; Kossakowski, K; Leroi, I; Londos, E; Minthon, L; Pozo-Rodriguez, F; Walker, Z, 2009) |
| " Patients were divided into 2 groups: 14 patients who received memantine in dosage 20 mg/d and 9 patients of a control group." | 2.73 | [Efficacy and safety of memantine in dementia with Lewy bodies]. ( Amosova, NA; Batukaeva, LA; Levin, OS; Smolentseva, IG, 2008) |
| " We selected global impression and cognitive function as primary efficacy outcomes, and dropouts and adverse events as safety outcomes." | 2.52 | Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. ( Jiang, T; Meng, XF; Tan, CC; Tan, L; Tan, MS; Tang, SW; Wang, C; Wang, HF; Yu, JT, 2015) |
| "Dementia with Lewy bodies and Parkinson's disease with dementia should be treated with rivastigmine." | 1.35 | [Treatment of degenerative dementia disorders--who should be treated?]. ( Hasselbalch, SG; Kampmann, JP, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (48.28) | 29.6817 |
| 2010's | 14 (48.28) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Giebel, C | 1 |
| Cations, M | 1 |
| Draper, B | 1 |
| Komuravelli, A | 1 |
| Hausner, L | 1 |
| Frölich, L | 1 |
| Rodda, J | 1 |
| Carter, J | 1 |
| Matsunaga, S | 1 |
| Kishi, T | 1 |
| Iwata, N | 1 |
| Wesnes, KA | 1 |
| Aarsland, D | 8 |
| Ballard, C | 7 |
| Londos, E | 6 |
| Wang, HF | 1 |
| Yu, JT | 1 |
| Tang, SW | 1 |
| Jiang, T | 1 |
| Tan, CC | 1 |
| Meng, XF | 1 |
| Wang, C | 1 |
| Tan, MS | 1 |
| Tan, L | 1 |
| Stubendorff, K | 1 |
| Larsson, V | 3 |
| Minthon, L | 5 |
| Levin, OS | 2 |
| Batukaeva, LA | 2 |
| Smolentseva, IG | 2 |
| Amosova, NA | 2 |
| Hasselbalch, SG | 1 |
| Kampmann, JP | 1 |
| Emre, M | 2 |
| Walker, Z | 1 |
| Bostrom, F | 1 |
| Alves, G | 1 |
| Kossakowski, K | 1 |
| Leroi, I | 1 |
| Pozo-Rodriguez, F | 1 |
| Johansson, C | 1 |
| Hansson, O | 1 |
| Palmqvist, S | 1 |
| Tsolaki, M | 1 |
| Bonuccelli, U | 1 |
| Destée, A | 1 |
| Tolosa, E | 1 |
| Kutzelnigg, A | 1 |
| Ceballos-Baumann, A | 1 |
| Zdravkovic, S | 1 |
| Bladström, A | 1 |
| Jones, R | 2 |
| O'Brien, JT | 1 |
| Burns, A | 2 |
| Engedal, K | 1 |
| Wattmo, C | 1 |
| Rongve, A | 1 |
| Broadstock, M | 1 |
| Svenningsson, P | 1 |
| Mathys, ML | 1 |
| McCarrell, J | 1 |
| Sleeper, RB | 1 |
| Blaszczyk, AT | 1 |
| Diehl, RR | 1 |
| Ridha, BH | 1 |
| Josephs, KA | 1 |
| Rossor, MN | 1 |
| Sabbagh, MN | 1 |
| Hake, AM | 1 |
| Ahmed, S | 1 |
| Farlow, MR | 1 |
| Menendez-Gonzalez, M | 1 |
| Calatayud, MT | 1 |
| Blazquez-Menes, B | 1 |
| Henriksen, AL | 1 |
| St Dennis, C | 1 |
| Setter, SM | 1 |
| Tran, JT | 1 |
| Johannsen, P | 1 |
| O'Brien, J | 1 |
| Auriacombe, S | 1 |
| Broich, K | 1 |
| Bullock, R | 1 |
| Feldman, H | 1 |
| Ford, G | 1 |
| Knapp, M | 1 |
| McCaddon, A | 1 |
| Iliffe, S | 1 |
| Jacova, C | 1 |
| Lennon, S | 1 |
| McKeith, I | 1 |
| Orgogozo, JM | 1 |
| Purandare, N | 1 |
| Richardson, M | 1 |
| Ritchie, C | 1 |
| Thomas, A | 1 |
| Warner, J | 1 |
| Wilcock, G | 1 |
| Wilkinson, D | 1 |
| Gallini, A | 1 |
| Sommet, A | 1 |
| Salandini, AM | 1 |
| Veyssière, P | 1 |
| Montastruc, JL | 2 |
| Alisky, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Memantine for Enhanced Stroke Recovery[NCT02144584] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2014-01-31 | Active, not recruiting | ||
| A Randomised, Double-blind, Placebo-controlled, 6-month Study of the Efficacy and Safety of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies[NCT00855686] | Phase 4 | 199 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| The Effect of High Frequency Repetitive Transcranial Magnetic Stimulation on Cognitive Impairment in Parkinson's Disease[NCT03879551] | 30 participants (Actual) | Interventional | 2019-03-15 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for memantine and Cortical Lewy Body Disease
| Article | Year |
|---|---|
[Cholesterol inhibitor and memantine in symptomatic dementia therapy].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cooperative Behavior; Dementi | 2013 |
Memantine for Lewy body disorders: systematic review and meta-analysis.
Topics: Excitatory Amino Acid Antagonists; Humans; Lewy Body Disease; Memantine; Patient Dropouts | 2015 |
Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis.
Topics: Antiparkinson Agents; Cholinesterase Inhibitors; Cognition Disorders; Humans; Lewy Body Disease; Mem | 2015 |
Cognitive impairment in Parkinson's disease and dementia with Lewy bodies.
Topics: Animals; Cholinesterase Inhibitors; Cognition Disorders; Humans; Lewy Body Disease; Memantine; Parki | 2016 |
Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia.
Topics: Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia; Humans; Lewy Body Disease; Memantine; | 2012 |
Visual hallucinations treated with the reinitiation of memantine in a patient with Lewy body dementia.
Topics: Aged; Dementia; Hallucinations; Humans; Lewy Body Disease; Male; Memantine; Nootropic Agents; Treatm | 2013 |
[Dementia].
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; | 2003 |
Dementia with lewy bodies: therapeutic opportunities and pitfalls.
Topics: Antiparkinson Agents; Antipsychotic Agents; Cholinesterase Inhibitors; Humans; Lewy Body Disease; Me | 2006 |
[Medical treatment of Alzheimer's disease].
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; | 2006 |
Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Combined Modality Therapy; Consensus Development | 2006 |
9 trials available for memantine and Cortical Lewy Body Disease
| Article | Year |
|---|---|
Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Attention; Cognition; Double-Bl | 2015 |
Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study.
Topics: Aged; Antiparkinson Agents; Dementia; Double-Blind Method; Female; Humans; Lewy Body Disease; Male; | 2014 |
[Efficacy and safety of memantine in dementia with Lewy bodies].
Topics: Aged; Antiparkinson Agents; Cognition; Dose-Response Relationship, Drug; Female; Follow-Up Studies; | 2008 |
Efficacy and safety of memantine in Lewy body dementia.
Topics: Aged; Antiparkinson Agents; Cognition; Dose-Response Relationship, Drug; Female; Follow-Up Studies; | 2009 |
Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.
Topics: Aged; Aged, 80 and over; Brain; Cognition; Cognition Disorders; Double-Blind Method; Excitatory Amin | 2009 |
Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment.
Topics: Aged; Aged, 80 and over; Dopamine Agents; Double-Blind Method; Female; Humans; Lewy Body Disease; Ma | 2011 |
Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial.
Topics: Accidental Falls; Aged; Aged, 80 and over; Dementia; Double-Blind Method; Europe; Female; Humans; In | 2010 |
Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial.
Topics: Accidental Falls; Aged; Aged, 80 and over; Dementia; Double-Blind Method; Europe; Female; Humans; In | 2010 |
Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial.
Topics: Accidental Falls; Aged; Aged, 80 and over; Dementia; Double-Blind Method; Europe; Female; Humans; In | 2010 |
Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial.
Topics: Accidental Falls; Aged; Aged, 80 and over; Dementia; Double-Blind Method; Europe; Female; Humans; In | 2010 |
The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia.
Topics: Aged; Aged, 80 and over; Dopamine Agents; Female; Humans; Lewy Body Disease; Male; Memantine; Outcom | 2010 |
Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson's disease dementia.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Dementia; Diagnostic and Statistical Manual of Men | 2011 |
10 other studies available for memantine and Cortical Lewy Body Disease
| Article | Year |
|---|---|
Ethnic disparities in the uptake of anti-dementia medication in young and late-onset dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cross-Sectional Studies; Dementia; Humans; Lewy Body D | 2023 |
[Antidementia Drug Therapy of Alzheimer's Dementia: Status 2018 and Outlook].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia, Vascular; Humans; Lewy Body Disease; Memanti | 2019 |
[Treatment of degenerative dementia disorders--who should be treated?].
Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Cholinesterase Inhibitors; Dementia; Dopamine Agents; | 2009 |
Memantine: a new hope for treatment of Lewy body-related dementias?
Topics: Aged; Brain; Brain Chemistry; Clinical Trials as Topic; Drug Interactions; Excitatory Amino Acid Ant | 2009 |
Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Dementia; Excitatory Amino Acid Antagonists; | 2011 |
Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine.
Topics: Age of Onset; Aged; Antiparkinson Agents; Brain; Cognition Disorders; Disease Progression; Hallucina | 2005 |
The use of memantine in dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; Dopamine Agents; Female; Humans; Lewy Body Disease; Male; Memantine; N-Meth | 2005 |
Exacerbation of Lewy bodies dementia due to memantine.
Topics: Aged; Alzheimer Disease; Dopamine Agonists; Hallucinations; Humans; Lewy Body Disease; Male; Memanti | 2005 |
Weight-loss associated with anti-dementia drugs in a patient with Parkinson's disease.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Anorexia; Antiparkinson Agents; Cholinesterase Inhibi | 2007 |
Memantine-induced decompensation in a patient with lewy body dementia.
Topics: Aged, 80 and over; Antiparkinson Agents; Female; Humans; Lewy Body Disease; Memantine; United States | 2007 |